Compare SURG & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | TXMD |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 25.9M |
| IPO Year | N/A | N/A |
| Metric | SURG | TXMD |
|---|---|---|
| Price | $1.28 | $2.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 339.5K | 153.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $50,372,555.00 | $2,796,000.00 |
| Revenue This Year | $3.78 | $427.09 |
| Revenue Next Year | $113.46 | N/A |
| P/E Ratio | ★ N/A | $106.16 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $1.05 | $0.72 |
| 52 Week High | $3.47 | $2.85 |
| Indicator | SURG | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 63.43 |
| Support Level | $1.16 | $2.36 |
| Resistance Level | $1.35 | $2.65 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 18.18 | 57.23 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.